Amylyx Pharmaceuticals, Inc. (AMLX)

The immediate narrative here is a classic 'dead cat bounce' turning into a speculative rally. After a catastrophic collapse from $93 in 2024 to roughly $2 in 2024, the stock staged a miraculous recovery to the high $30s in late August, erasing nearly all losses in a matter of weeks. This isn't driven by a turnaround in fundamentals—the company remains unprofitable with negative free cash flow and a negative forward P/E—so the move is purely speculative. However, the options market is screaming bullishness, with traders buying calls at strikes that would require a 30-50% gain from current levels, while almost no one is hedging with puts. This asymmetry suggests a high-risk, high-reward momentum play rather than a value investment. The statistical forecast model offers a weak lean upward, which aligns with the options flow but lacks the conviction to stand alone against the fundamental reality of the business. For investors, this is a binary bet on whether the Avexitide catalyst can drive a sustained re-rating, or if the recent surge was a final liquidation event. Given the lack of dividends and weak long-term earnings trajectory, this is strictly a short-to-intermediate term momentum trade, not a buy-and-hold opportunity.